



Farm Products Council of Canada
Conseil des produits agricoles du Canada

Central Experimental Farm
Building 59
960 Carling Avenue
Ottawa, Ontario K1A 0C6

Ferme expérimentale centrale
Édifice 59
960, avenue Carling
Ottawa, Ontario K1A 0C6

July 17, 2026

Mr. Roger Pelissero
Chair
Egg Farmers of Canada
21 Florence Street
Ottawa, Ontario K2P 0W6

Subject: Amendments to the *Canadian Egg Marketing Agency Quota Regulations, 1986*

Dear Mr. Pelissero,

On July 17, 2026, the Farm Products Council of Canada (Council) reviewed the proposed amendments to Schedule 2 (Vaccine Quota) of the *Canadian Egg Marketing Agency Quota Regulations, 1986*, as outlined in your letter of June 29, 2026, for the allocation period that begins on December 27, 2026, and ends on December 25, 2027.

Following a thorough review of the rationale provided by the Egg Farmers of Canada and internal analysis, Council members found that the amendments are necessary for the implementation of the marketing plan as per the *Canadian Egg Marketing Agency Proclamation*. The amendments will come into force on December 27, 2026.

Should you have any questions, please do not hesitate to contact me or Lisa Melanson-Daigle, Council Secretary, by email at fpcc.secretariat.cpac@fpcc-cpac.gc.ca.

Sincerely,

Brian Douglas
Chair

June 29, 2026

Mr. Brian Douglas
Chair
Farm Products Council of Canada
Central Experimental Farm
Building 59, 960 Carling Avenue
Ottawa, ON K1A 0A6

Re: 2027 Vaccine Quota Allocation Amendment

Dear Brian,

Following the vaccine sovereignty crisis during the COVID-19 pandemic, the Government of Canada encouraged the development of an expanded vaccine production industry in Canada. The result was that Sanofi Canada (formerly Sanofi Pasteur) (Sanofi) developed a vaccine production facility in Mississauga, Ontario, with vaccine production due to start in January 2027. Valo BioMedia Inc. (Valo) has been contracted by Sanofi to produce the required number of embryos for vaccine production.

Planning for this production and ensuring the supply of vaccine eggs comes under the auspices of Supply Management. These efforts have been going on for several years between Egg Farmers of Canada (EFC), Egg Farmers of Ontario (EFO), Sanofi, and Valo. In consultation with EFC staff and lawyers, EFO has developed regulations and a policy to manage vaccine egg production in Ontario destined for the Sanofi production facility.

Consistent with the current production model for GSK Canada (GSK) vaccine eggs, new quota layers would be allocated to Ontario to support Sanofi vaccine egg production. These layers would commence egg production for vaccine manufacturing effective January 1 of each year. This means the layers would be placed in barns in and around November of the previous year. In normal years, the additional production of vaccine eggs would help mitigate the costs of import assistance in the lead up to the holidays.

After consultation between Sanofi and Valo, EFO has submitted a request (See Appendix A) for the number of layers required to produce vaccine eggs for Sanofi in 2027. As part of EFC's commitment towards an expanded vaccine production industry, this quota allocation request is being made now, to ensure everything will be in place as of January 1, 2027.

After having duly considered the overbase factors in the Proclamation and EFC's objects, the EFC Board of Directors approved the Vaccine quota allocation (found in Schedule 2.0 of *Canadian Egg Marketing Agency Quota Regulations, 1986*) for Ontario for 6,716,666 dozens (the equivalent of 492,000 layers) for the period from December 27, 2026, to December 25, 2027.

Drafting instructions reflecting the amendment have been provided to Farm Products Council of Canada at the same time as the Department of Justice.

At a rate of lay of 27.30 dozen eggs per layer per year (see Appendix A for explanation), please see Schedule 2.0 for the period from December 27, 2026 to December 25, 2027.

Schedule 2.0 Dec. 27, 2026-Dec.25, 2027		
	Vaccine Quota (layer)	Limits to Vaccine Quota (doz.)
ON	492,000	6,716,666
TOTAL:	492,000	6,716,666

In accordance with EFC's normal process, a full review of the 2027 Vaccine Quota Allocation will be completed in the fall of 2026. This will include reviewing the required vaccine quota allocation layers for vaccine egg production from both GSK and Sanofi, and may result in a further amendment to Schedule 2.0 of the *Canadian Egg Marketing Agency Quota Regulations, 1986* for the period from December 27, 2026, to December 25, 2027.

Feel free to contact me should you have questions.

Sincerely,



Roger Pelissero
Chair

copy: EFC Board of Directors
FPCC Members
Drew Black, Chief Executive Officer
Neil Newlands, Chief Operating Officer

Encl.



7195 Millcreek Drive, Mississauga, ON L5N 4H1

PHONE 905-858-9790 FAX 905-858-1589

www.getcracking.ca

Via Email: NNewlands@eggs.ca

May 11, 2026

Mr. Neil Newlands
Chief Operating Officer
Egg Farmers of Canada
21 Florence Street
Ottawa, Ontario K2P 0W6

Dear Mr. Newlands,

Re: Vaccine Quota Request for 2027

On behalf of Egg Farmers of Ontario (EFO), I am writing to formally request a vaccine egg quota allocation for the 2027 production year in support of influenza vaccine production in Ontario.

Beginning in 2027, Ontario producers will be supplying vaccine eggs under a confirmed commercial program between Sanofi and VALO BioMedia Canada Inc. This initiative establishes a new and dedicated vaccine egg production stream in Ontario and requires a corresponding quota allocation to ensure a stable, compliant supply.

The program is structured around four Ontario contract producers, each operating two barns with a net capacity of approximately 61,500 females per barn, resulting in a total laying capacity of approximately 492,000 hens.

Based on confirmed production requirements, installed capacity, and the conversion methodologies historically applied to vaccine quota allocations, EFO is requesting a vaccine quota allocation equivalent to **492,000 layers** for the 2027 production year to meet a targeted need of 2.67 million embryos per week. This conversion is illustrated in the table below.

Number of birds	492,000
Eggs per week	3,100,000
Eggs per year (for 26 weeks)	80,600,000
Dozen eggs per year (for 26 weeks)	6,716,666
Embryos per week	2,667,000
Embryos per year (for 26 weeks)	69,342,000
Dozen embryos per year (for 26 weeks)	5,778,500
Rate of lay	27.30



7195 Millcreek Drive, Mississauga, ON L5N 4H1

PHONE 905-858-9790 FAX 905-858-1589

www.getcracking.ca

The difference between eggs produced per week and usable embryos per week reflects the biological and handling factors inherent in vaccine egg production. Not every egg laid is suitable for incubation. Eggs laid on the floor, eggs that fall outside size specifications, and dirty eggs are removed at the farm level. Following incubation, additional losses occur due to infertility, early embryo mortality, cracks, or improper embryo orientation. Based on these standard industry parameters, approximately 86% of eggs are expected to yield viable embryos suitable for vaccine production.

The rate of lay assumption used in this calculation is based on an average hen-day production of approximately 90% over the 26-week vaccine production period. This rate reflects the shorter, high-productivity laying window associated with vaccine egg programs, where flocks are utilized primarily during peak production rather than over a full commercial laying cycle. The program will also utilize white-egg genetics, which typically demonstrate strong early-cycle productivity. These factors result in a slightly higher average rate of lay than that observed in some other vaccine quota calculations.

The requested allocation will be used to meet the vaccine demand from Week 1 to 26 of 2027, where 11-day old embryos are used from flocks that are older than 24 weeks. The flocks will be depopulated shortly after Week 26. The next flock will be placed in October which means a downtime period of four months between flocks.

EFO respectfully requests that the EFC Board review and approve this allocation as part of the 2027 vaccine quota framework. We would be pleased to provide additional technical information or facilitate further discussion with the vaccine manufacturer if required.

Thank you for your consideration.

Sincerely,

A handwritten signature in black ink, appearing to read 'R. Brown'.

Ryan Brown, CEO
Egg Farmers of Ontario

RB/tm